Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Farmers Insurance
Daiichi Sankyo
US Army
Teva
QuintilesIMS
Julphar
Chubb
Johnson and Johnson

Generated: April 20, 2018

DrugPatentWatch Database Preview

RANOLAZINE Drug Profile

« Back to Dashboard

When do Ranolazine patents expire, and when can generic versions of Ranolazine launch?

Ranolazine is a drug marketed by Lupin Ltd and is included in one NDA.

The generic ingredient in RANOLAZINE is ranolazine. There are nineteen drug master file entries for this compound. Three suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the ranolazine profile page.
Drug patent expirations by year for RANOLAZINE
Medical Subject Heading (MeSH) Categories for RANOLAZINE
Synonyms for RANOLAZINE
( )-Ranolazine
(-)-Ranolazine
(+-)-N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
(+-)-Ranolazine
(+/-)-1-(3-(2-Methoxyphenoxy)-2-hydroxypropyl)-4-(n-(2,6-dimethylphenyl)carbamoylmethyl)piperazine
(+/-)-4-(2-Hydroxy-3-(o-methoxyphenoxy)propyl)-1-piperazineaceto-2',6'-xylidide
1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+-)-
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-
110445-25-5
142387-99-3
4CA-1078
635R555
95635-55-5
A11162
AB0007809
AB00698532_16
AB00698532_17
AB00698532_18
AB00698532-11
AB00698532-13
AB00698532-14
AB00698532-15
AB2000299
AC-1673
AC-3497
AC1L1M17
AC1Q5LYD
ACT06286
AK-72950
AKOS015889500
AN-5494
BC205445
BCP0726000090
BCP9000558
BDBM50173335
BR-72950
BRD-A97674275-001-01-9
BSPBio_002276
C24H33N3O4
CAS-95635-55-5
CCG-205139
CHEBI:87690
CHEMBL1404
CR0012
CS-2292
CTK3I7295
CVT 303
CVT 303;RS 43285-003
CVT-303
D03HYQ
D05700
D06TES
DB00243
DR002639
DSSTox_CID_25196
DSSTox_GSID_45196
DSSTox_RID_80743
DTXSID3045196
FT-0601594
GTPL7291
H959
HE292530
HE419447
HMS1922F16
HMS2090L09
HMS2093D21
HMS2098K06
HMS2230C19
HMS3369I08
HMS3655M12
HSDB 7924
HY-B0280
I01-2008
I06-0160
KB-298373
KEG-1295
KS-00000JS7
KS-1244
Latixa
Lopac0_001062
LS-187267
MCULE-8182023610
MFCD00864690
MLS002154149
MolPort-003-666-653
N-(2,6-Dimethyl-phenyl)-2-{4-[2-hydroxy-3-(2-methoxy-phenoxy)-propyl]-piperazin-1-yl}-acetamide
N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}ethanimidic acid
N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
N-(2,6-DIMETHYLPHENYL)-4-[2-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]PIPERAZIN-1-YL]ACETAMIDE
N-(2,6-DIMETHYLPHENYL)-4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETAMIDE
NCGC00015897-02
NCGC00015897-03
NCGC00015897-04
NCGC00015897-05
NCGC00015897-06
NCGC00015897-08
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
NSC-759100
NSC759100
PB21724
Pharmakon1600-01505366
RAN D
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
Ranolazine 1g
Ranolazine (Ranexa)
Ranolazine (USAN/INN)
Ranolazine [USAN:INN:BAN]
Ranolazine 2HCl
Ranolazine/Dronedarone Fixed-Dose Combination
renexa
RS-43285
RS-43285-003
S-1794
s1799
SBI-0051032.P002
SC-25810
SCHEMBL124665
SMR000857382
SPECTRUM1505366
ST24025536
Tox21_110258
Tox21_110258_1
TR-031802
XKLMZUWKNUAPSZ-UHFFFAOYSA-N
Z68563450

US Patents and Regulatory Information for RANOLAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd RANOLAZINE ranolazine TABLET, EXTENDED RELEASE;ORAL 201046-001 Jul 29, 2013 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Ltd RANOLAZINE ranolazine TABLET, EXTENDED RELEASE;ORAL 201046-002 Jul 29, 2013 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Harvard Business School
US Army
Johnson and Johnson
Boehringer Ingelheim
Queensland Health
Cantor Fitzgerald
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.